Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RVPH
RVPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RVPH News
Reviva Pharmaceuticals Closes $10 Million Public Offering
6d ago
NASDAQ.COM
Reviva Pharmaceuticals Raises Funds for Schizophrenia Trial
Mar 19 2026
stocktwits
Reviva Pharmaceuticals Prices Public Offering at $1.50 per Share
Mar 19 2026
NASDAQ.COM
Reviva Pharmaceuticals Shares Plunge 42% Following Proposed Public Offering
Mar 19 2026
NASDAQ.COM
Reviva Pharmaceuticals Plans Public Offering of Stock and Warrants
Mar 18 2026
seekingalpha
Reviva Pharmaceuticals CEO to Present at Neuroscience Innovation Forum in San Francisco
Dec 29 2025
Globenewswire
Reviva Pharmaceuticals CEO to Present at 9th Annual Neuroscience Innovation Forum
Dec 29 2025
Newsfilter
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Reviva Pharmaceuticals Initiates Second Phase 3 Trial RECOVER-2, Delaying NDA Submission to 2027
Dec 24 2025
NASDAQ.COM
Reviva Pharmaceuticals Shares Plunge 45.9%, Dragging Down Drug Sector
Dec 23 2025
NASDAQ.COM
Dow Jones Index Gains Over 100 Points as Durable Goods Orders Decline 2.2%
Dec 23 2025
Benzinga
U.S. GDP Grows 4.3% Annually, Highest in Two Years
Dec 23 2025
Benzinga
Reviva Pharmaceuticals Plans Second Phase 3 Trial for Brilaroxazine in 2026 Following FDA Feedback
Dec 23 2025
Benzinga
Reviva Plans to Initiate Second Phase 3 Trial for Brilaroxazine in 2026
Dec 23 2025
Globenewswire
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
Dec 01 2025
NASDAQ.COM
D. Boral Capital Reiterates Buy Rating on Reviva Pharmaceuticals with $2 Price Target Intact
Nov 19 2025
Benzinga
Show More News
